August 25, 2021

Brilliant Futures™ Acceleration Workshop Enhances In-Practice Success
with Communication, Staff Engagement and Business Growth Strategies

SAN RAMON, Calif., Aug. 25, 2021—With the number of Brilliant Futures™ Certified eye care professionals in the U.S. now exceeding 4,600, CooperVision convened select prescribers in Chicago Aug. 19–20 to support the continued growth of myopia management in U.S. eye care practices.  

During the intensive workshop, attendees dove into parent communication insights, staff engagement strategies, and practice marketing tips that can enhance a practice’s success with the Brilliant Futures™ Myopia Management Program featuring MiSight® 1 day contact lenses.

“I became a MiSight® provider less than a year ago and now I wanted to take it to the next level with some additional marketing tools and more confidence communicating about it with my age-appropriate* patients and their parents,” said Stacie Setchell, OD, Virdi Eye Clinic. “This workshop was well worth coming to. This has been great.”

“As a pediatric ophthalmologist, I’m really passionate about incorporating myopia management into my practice,” said Grace Shin, MD, MPH, Ideal EyeCare. “With the pandemic and people on devices, it’s a really good time to educate people about treatments that can make a difference in their children’s lives.”

Two Brilliant Futures™ certified ECPs—Maria Liu, OD, PhD, MPH, MBA, FAAO, and Ashley Wallace-Tucker, OD, FAAO— shared their myopia management tips with their peers. Attendees also learned from Steve Vargo, OD, MD, optometric practice management consultant, Tara O’Grady, ALLDOCs managing director, Mike McDougall, APR, Fellow PRSA, president of McDougall Communications, and CooperVision’s Michele Andrews, OD, Justin Kwan, OD, FAAO, and Kelly Volz, OD, FAAO FSLS.

“Act today to change tomorrow,” says Kwan, Senior Manager of Myopia Management, CooperVision. “That’s that the choice that every Brilliant Futures™ certified ECP made when they brought the only FDA-approved* myopia control contact lens in children aged 8-12 at the initiation of treatment, MiSight 1 day, into their practices. Now, through partnership, we can grow the impact of their efforts.”

For more information about the Brilliant Futures Myopia Management Program and MiSight 1 day, eye care professionals can visit or connect with their CooperVision sales representative.

# # #

*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit

Media Contact
Hannah Barry, McDougall Communications or +1-585-645-8985